Robert S Wallis
Affiliation: University of North Carolina
- Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockadeRobert S Wallis
PPD Inc, Washington, DC 20005, USA
Arthritis Rheum 58:947-52. 2008..These 2 pathogenic mechanisms cannot otherwise be readily distinguished...
- Reconsidering adjuvant immunotherapy for tuberculosisRobert S Wallis
PPD, Washington, DC, USA
Clin Infect Dis 41:201-8. 2005..Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas...
- Reactivation of latent granulomatous infections by infliximabRobert S Wallis
University of Medicine and Dentistry New Jersey, New Jersey Medical School, Newark, New Jersey, USA
Clin Infect Dis 41:S194-8. 2005..The ability of infliximab to disrupt established granulomas may be distinct from its ability to neutralize soluble TNF. Further research to elucidate the mechanism of the antigranuloma activity of infliximab is warranted...
- Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximabRobert S Wallis
UMDNJ New Jersey Medical School, Newark, NJ, USA
Semin Arthritis Rheum 34:34-8. 2005..TNF is known to participate in the induction and maintenance of protective granulomas at multiple steps, and evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed...
- Reactivation of latent tuberculosis by TNF blockade: the role of interferon gammaRobert S Wallis
PPD, Washington, DC, USA
J Investig Dermatol Symp Proc 12:16-21. 2007..IL-10 production was equally suppressed by all three drugs, excluding excess IL-10 as a regulatory mechanism. The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFNgamma...
- Acquired rifamycin resistance: pharmacology and biologyRobert S Wallis
UMDNJ NJ Medical School, 1213 N Street NW, Suite A, Washington, DC 20005 USA
Expert Rev Anti Infect Ther 6:223-30. 2008..Limiting TB therapy to weekdays may promote the emergence of acquired drug resistance in patients with advanced AIDS and TB. A large, simple trial to examine this question is both warranted and feasible...
- Tumor-necrosis-factor blockers: differential effects on mycobacterial immunityOluwabunmi Y Saliu
Department of Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA
J Infect Dis 194:486-92. 2006..tuberculosis. None of the drugs induced significant levels of apoptosis or necrosis, in either monocytes or T cells. CONCLUSIONS: The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFN- gamma ...
- Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunityErnestas Janulionis
UMDNJ-New Jersey Medical School, Newark, New Jersey, USA
Infect Immun 73:2595-601. 2005..Our findings indicate substantial variability in the capacity of clinical tuberculosis isolates to replicate in host cells in the face of innate host immunity...
- Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosisOluwabunmi Y Saliu
UMDNJ New Jersey Medical School, 185 S Orange Avenue, MSB 185, Newark, NJ, USA
J Antimicrob Chemother 60:994-8. 2007..The present study was conducted to determine the activity of OPC-67,683 in the in vitro tolerance model using drug-tolerant clinical Mycobacterium tuberculosis strains...
- Tumour necrosis factor antagonists: structure, function, and tuberculosis risksRobert S Wallis
PPD Inc, Washington, DC, USA
Lancet Infect Dis 8:601-11. 2008..Clinical strategies for prevention and management of tuberculosis in patients treated with TNF blockers may be improved based on our evolving understanding of these differences...
- Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood cultureErnestas Janulionis
University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, USA
Antimicrob Agents Chemother 48:3133-5. 2004..Clofazimine was inactive whether it was tested alone or combined with other drugs that are used to treat multidrug-resistant tuberculosis, despite a total dose of 2 g. Kanamycin was the most active drug tested...
- Whole blood bactericidal activity during treatment of pulmonary tuberculosisRobert S Wallis
Department of Medicine, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, NJ 07103, USA
J Infect Dis 187:270-8. 2003..018), both of which are indicative of prognosis. These findings indicate that measurement of WBA may have a role in assessing the sterilizing activity of new anti-TB drugs...
- A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)Robert S Wallis
The University Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
J Acquir Immune Defic Syndr 32:281-6. 2003..The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted...
- Persistence, not resistance, is the cause of loss of isoniazid effectRobert S Wallis
J Infect Dis 195:1870-1; author reply 1872-3. 2007
- Structural-functional relationships of TNF-alpha antagonists: next stepsFrank J Dann
Amgen Inc, Thousand Oaks, California 91320 1799, USA
J Investig Dermatol Symp Proc 12:46-7. 2007..The data presented in this supplement highlight the need for further research into these key areas, and illustrate our current understanding of the mode of action of TNF blockers as only the tip of the iceberg...
- TB chemotherapy: antagonism between immunity and sterilizationRobert S Wallis
Am J Respir Crit Care Med 169:771-2. 2004
- Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?Robert S Wallis
Am J Respir Crit Care Med 172:4-5. 2005
- Anti-tuberculosis treatment and infliximabRobert S Wallis
Respir Med 99:1620-2. 2005
- Granulomatous infections due to tumor necrosis factor blockade: correctionRobert S Wallis
Clin Infect Dis 39:1254-5. 2004
- A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosisRobert S Wallis
Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
AIDS 18:257-64. 2004..This phase 1 study examined the safety, microbiology, immunology, and virology of TNF blockade using etanercept (soluble TNF receptor, Enbrel) during the initial treatment of HIV-associated tuberculosis...
- Surrogate markers to assess new therapies for drug-resistant tuberculosisRobert S Wallis
Expert Rev Anti Infect Ther 5:163-8. 2007
- Here today--gone tomorrow: the case for transient acute tuberculosis infectionEdward A Nardell
Am J Respir Crit Care Med 174:734-5. 2006
- Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG studyRob Roy MacGregor
Infectious Diseases Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
AIDS Res Hum Retroviruses 21:689-95. 2005..MAC-specific T cell responses apparently develop and persist during DMAC, but are dysfunctional or too infrequent to prevent persistence...
- Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in UgandaHarriet Mayanja-Kizza
Department of Medicine, Makerere University Medical School, Kampala, Uganda
J Infect Dis 191:856-65. 2005..Conclusion. The benefits of prednisolone therapy on immune activation and CD4(+) T cell counts do not outweigh the risks of adverse events in HIV-infected patients with TB and preserved immune function...
- Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosisSeon-Hee Cheon
Case Western Reserve University, Cleveland, Ohio, USA
Clin Diagn Lab Immunol 9:901-7. 2002..These experiments indicate that whole blood culture may be used to measure immunity to M. tuberculosis and that further studies of repeated BCG vaccination are warranted...